Cocrystal Pharma Business Summary

Cocrystal Pharma, Inc. (COCP) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements, research collaborations, and government-funded grants. Its business model centers on a proprietary structure-based drug discovery platform that utilizes protein crystallography to develop small-molecule antivirals targeting highly conserved replication machinery. The company’s primary business segments are categorized by viral indication, including Norovirus (CDI-988), Influenza (CC-42344), and Coronavirus, with a secondary focus on Hepatitis C (CC-31244). Cocrystal competes directly with antiviral developers such as Enanta Pharmaceuticals, Aligos Therapeutics, and TScan Therapeutics; it distinguishes itself in the market by focusing on broad-spectrum, "best-in-class" inhibitors designed to remain effective against rapidly mutating viral strains. The company is led by Co-CEOs Dr. Sam Lee, who serves as President with over 25 years of anti-infective research experience from Icos Corporation, and James J. Martin, who serves as CFO with a background in financial leadership at Motus GI and VBI Vaccines. The founding team and board are anchored by world-renowned scientific and financial pedigree, most notably Chairman of the Board and Chief Scientist Dr. Roger Kornberg, a 2006 Nobel Laureate in Chemistry. Significant institutional and insider backing is provided by billionaire investor Dr. Phillip Frost, Chairman and CEO of OPKO Health and former Chairman of Teva Pharmaceuticals, who remains a major shareholder and director. Other key board members include Vice Chairman Steve Rubin and former Schering-Plough CEO Fred Hassan, providing the firm with deep industry expertise in pharmaceutical commercialization and governance.